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Review Article
Abstract: Inherited primary arrhythmia syndromes are genetically deter-
mined disorders of cardiac ion channels or ion channel macromolecular com-
plexes usually associated with a higher risk of sudden cardiac death. These 
conditions have a very broad spectrum of clinical manifestations, ranging 
from an asymptomatic course to syncope, atrial and ventricular arrhythmias, 
and conduction disturbances, but may produce sudden infant death syndrome 
and unexplained sudden cardiac death in apparently healthy individuals. Dur-
ing the last 20 years, the evolving knowledge on the genetic basis of inherited 
arrhythmia syndromes has dramatically reshaped our understanding of these 
conditions and, consequently, had a great impact on patient care. Based on 
the knowledge of the genetic substrates, specific risk factors for individual 
genotypes have been identified, and various investigations have been launched 
with the intention of developing a gene- and even mutation-specific therapy. 
Preliminary results from animal studies suggest that gene therapy rescues the 
normal ion channel function and thereby prevents cardiac events in some pri-
mary arrhythmia syndromes, which suggests that upon appropriate validation 
in a clinical setting, it may become available for affected patients. The pur-
pose of this review is to provide clinicians with a contemporary insight into 
the role of genetic testing in the diagnosis, therapy, and prognosis of patients 
with primary arrhythmia syndromes, and the clinical implications of screen-
ing family members who are at risk of sudden cardiac death.
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(Cardiology in Review 2019;27: 23–33)
Inherited primary arrhythmia syndromes are genetically determined cardiac diseases caused by mutations in genes encoding cardiac 
ion channels and associated regulatory proteins (Fig. 1).1 These dis-
orders usually follow the Mendelian inheritance pattern, frequently 
present in the early years of life, and can cause cardiac arrest and/or 
sudden cardiac death (SCD) among young and apparently healthy 
individuals.2 Genetic testing in these diseases has important implica-
tions in diagnosis, prognosis, and therapy.1,3 Important features of 
cardiac channelopathies are variable clinical phenotype and variable 
expression of the disease in which vulnerability to arrhythmias and 
disease progression is determined by the multifaceted interplay of 
the mutation characteristics, epigenetic and environmental factors.4 
Many of these diseases exhibit overlapping phenotypes, and the pre-
cise genetic diagnosis allows specific therapy. The recent advances 
in next-generation sequencing technologies have provided clinicians 
and researchers with unique tools to better understand the genetic 
aspects of these diseases. Here we summarize the current knowledge 
on genotype–phenotype associations in inherited arrhythmia syn-
dromes, with a focus on important clinical implications of the genetic 
test in the management of affected patients and their relatives. Due to 
their controversial impact on clinical application, we did not include 
in this review the genetic basis of atrial fibrillation (AF) and idio-
pathic ventricular fibrillation (VF).
LONG QT SYNDROME
The congenital long QT syndrome (LQTS) is a genetically 
determined cardiac arrhythmia syndrome characterized by a pro-
longation of the QT interval on the electrocardiogram (ECG) and 
an increased propensity to syncope, seizures, polymorphic ventricu-
lar tachycardia (VT) (typically, torsades de pointes), cardiac arrest, 
and SCD in individuals with structurally normal hearts (Fig. 2).5,6 
The prevalence of congenital LQTS is estimated in the range of 
1:2000–1:2500.7
Diagnosis of LQTS
The diagnosis of LQTS relies on symptoms, QT interval dura-
tion in the 12-lead ECG corrected for heart rate (QTc), clinical and 
family history, and genetic test results.8 Based on these parameters, 
Schwartz and Crotti9 proposed a scoring system that allows deter-
mining the probability of having LQTS (Table 1).9 Currently, LQTS 
is diagnosed in the presence of a QTc interval ≥500 milliseconds, 
an unequivocally pathogenic mutation in one of the LQTS genes, 
or a LQTS risk score ≥3.5 in the absence of secondary causes of 
QTc prolongation.8 The diagnosis can also be made in the presence 
of a QTc between 480 and 499 milliseconds in repeated ECGs in 
a patient with unexplained syncope, in the absence of a secondary 
cause for QT prolongation and in the absence of a pathogenic muta-
tion.3,8 The diagnosis or exclusion of LQTS solely relying on QTc 
values should be avoided because nearly 30% of patients hosting 
pathogenic mutations in LQTS genes display normal QTc intervals; 
thus, the Schwartz criteria are an invaluable tool for the selection of 
candidates for further testing.10
Genetics Basis of LQTS and Implications of the 
Genetic Test in LQTS
To date, 16 genes have been associated with LQTS (Sup-
plementary Table 1, http://links.lww.com/CIR/A15). The major 
LQTS genes are KCNQ1 (LQTS1), KCNH2 (LQTS2), and SCN5A 
(LQTS3), which collectively account for approximately 90% of 
all genotype-positive cases.11 Nearly 8% of LQTS patients host 
compound heterozygous mutations.12 Thirteen minor LQTS genes 
together explain approximately 5–10% of cases. These include 3 
genes that cause multisystem syndromic disorders associated or not 
associated with prolonged QTc values: ankyrin-B syndrome (ANK2, 
LQTS4), Andersen–Tawil syndrome (ATS) (KCNJ2, LQTS7), and 
Timothy syndrome (CACNA1C, LQTS8).
Diagnostic Value
The yield of genetic testing in LQTS reaches 70–80% (Fig. 3).13 
Identification of a clear LQTS-associated mutation in any major gene 
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is considered diagnostic, regardless of QTc duration (Table 2). The 
overall penetrance (proportion of mutation carriers who develop 
the disease) is estimated to be nearly 40%14 but is reported in the 
range of 25–100% among different LQTS subtypes and dependent 
on mutation localization.15–18 Genotyping is particularly important 
in patients with a high probability of LQTS (Schwartz score, >3).1 
However, the clinical diagnosis of LQTS will not be swayed by a neg-
ative genetic test, which occurs in 20% of “unquestionable LQTS” 
(Schwartz score, ≥3.5) cases because these patients have a lower risk 
for arrhythmias than the genotype positives, but have a considerable 
risk for arrhythmic events.19
Genotype–Phenotype Correlation
LQTS1 (KCNQ1), LQTS5 (KCNE1), and LQTS11 (AKAP9) 
are caused by defective I
Ks
, the slow component of the delayed rec-
tifier potassium current (I
K
). KCNQ1 and KCNE1 genes encoding 
respectively the α and β subunits of the voltage-gated potassium 
channel, which conducts the I
Ks
 current, whereas A kinase anchor-
ing protein 9 (AKAP9) facilitates the phosphorylation of KCNQ1 
by protein kinase A and thereby augments the I
Ks
 current. KCNQ1 
is the most common cause of LQTS and accounts for 30–35% of 
all genotype-positive cases. Homozygous or compound heterozy-
gous mutations in KCNQ1 or KCNE1 produce autosomal recessive 
Jervell–Lange–Nielsen syndrome, characterized by severe LQTS 
phenotype, as evidenced by a QTc >500 milliseconds, a high rate 
of sudden death, and sensorineural deafness.20 Patients with LQTS1 
typically have a QTc prolongation and broad-based T wave on rest-
ing ECG.21 KCNQ1 mutations also account for over 90% of fetal 
bradycardias.22 Mutations in KCNQ1 predispose affected individuals 
to arrhythmias during times of physical (62%) or emotional duress 
(26%) owing to the inability of the cardiomyocytes to adopt (shorten) 
the repolarization duration to the rising heart rate due to defective I
Ks
 
current.23
LQTS2 (KCNH2) and LQTS6 (KCNE2) are caused by defective 
I
Kr
 current, the fast component of I
K
. KCNH2 and KCNE2 encode respec-
tively the α (HERG) and β subunits MinK-related peptide 1 (MIRP) of 
the potassium channel that generate the I
Kr
 current.24,25 KCNH2 mutations 
explain nearly 25–30% of LQTS cases. The ECG is remarkable for a 
low-amplitude, notched or biphasic T wave (Fig. 2)21 but may be normal 
in 20% of KCNH2 mutation carriers.10 Patients with LQTS2 often pres-
ent with syncope and cardiac arrest in response to emotional stressors 
(43%), including unexpected auditory stimuli such as sudden noises and 
BA
FIGURE 1. Schematic representation of cardiomyocyte ion channel structural elements implicated in the pathogenesis of the car-
diac channelopathies. A, The main membrane channels responsible for cardiac action potential. B, Sarcoplasmic calcium-release 
complex. ATP indicates, adenosine triphosphate; ICaL, calcium current; INa, sodium current; IKr, rapid component of the delayed 
rectifier potassium current; If, pacemaker ('funny') current; SERCA2a, sarcoplasmic/endoplasmic reticulum calcium ATPase 2a.
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FIGURE 2. Characteristic ECG patterns in inherited primary arrhythmia syndromes. Long QT syndrome type 1–3 (A–C), and 
torsades de pointes (D); Brugada syndrome (E); short QT syndrome type 1–3 (F–H); and polymorphic (bidirectional) ventricular 
tachycardia in response to increased exercise load, characteristic for catecholaminergic polymorphic ventricular tachycardia (I). 
Note the characteristic features of the torsades de pointes arrhythmia: the prolonged QT interval with distorted T-U complex, 
the arrhythmia initiating short-long-short ventricular cycle sequence triggered by a PVC, the “warm-up” phenomenon with 
initial R-R cycles longer than subsequent cycles, and the abrupt switching of QRS morphology from predominately positive to 
predominately negative complexes (*). ECG indicates electrocardiogram; PVC indicates premature ventricular contraction.
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telephone ringing (26%), particularly when occurring at rest (64%).23 
An association of LQTS2 with seizures has been documented.26 
Women with LQTS2 are particularly at risk in the postpartum period, 
and during the menopause transition and postmenopausal periods.27 
In contrast to LQTS1, arrhythmias in LQTS2 are rarely triggered 
by exercise (13%) and occur twice more frequently while at rest or 
asleep (29%).23
There are few cases of LQTS6 reported in the literature; how-
ever, no genotype–phenotype segregation has been documented. A 
recent study has found that KCNE2 variants may be insufficient in 
isolation to cause LQTS but may confer proarrhythmic susceptibility 
when provoked by additional QTc modifiers.28
LQTS3 (SCN5A), LQTS9 (CAV3), LQTS10 (SCN4B), and 
LQTS12 (SNTA1) are caused by defective inward late sodium cur-
rent (I
Na
). Na
V
1.5 cardiac sodium channel, encoded by SCN5A, con-
ducts the I
Na
 current responsible for phase 0 depolarization.29 LQTS3 
is caused by heterozygous gain-of-function mutations in the SCN5A 
and accounts for 5–10% of genotype-positive LQTS cases. LQTS3 
penetrance reaches 90%.30 Gain-of-function mutations in SCN5A 
prolong the QT interval via small net increase in the I
Na
 current. 
Patients with LQTS3 often experience arrhythmias and cardiac arrest 
while at rest (39%), particularly during sleep when increased vagal 
tone favors slower heart rate.23 In these patients, prolongation of the 
ST-segment accounts for QT prolongation and is typically followed 
by a T wave of relatively small amplitude (Fig. 2).21
LQTS4 (ANK2) is caused by defective ankyrin-B protein. 
Loss-of-function mutations in ANK2 abolish the ability of ankyrin-
B to restore abnormal calcium dynamics and abnormal localization 
and expression of Na/Ca exchanger, Na/K adenosine triphosphate 
(ATPase), and inositol trisphosphate receptor in cardiomyocytes.31 
These functional impairments lead to calcium accumulation in the 
cytoplasm and cause early and delayed after-depolarizations, typically 
in response to catecholaminergic stimulation. These malfunctions 
produce varying degrees of cardiac dysfunction, bradycardia, sinus 
arrhythmia, bidirectional VT, VF, and risk of sudden death, collec-
tively called “ankyrin-B syndrome.” These patients have inconsistent 
and variable QTc prolongation, indicating that ankyrin-B syndrome 
represents a separate clinical entity with features overlapping with 
LQTS (LQTS4) and catecholaminergic polymorphic VT (CPVT).
LQTS7/ATS (KCNJ2) is caused by defective Kir2.1, a critical 
component of the inward rectifier potassium current (I
K1
).32 Muta-
tions within KCNJ2 cause ATS,33 a rare, autosomal dominant dis-
order (≈1:500,000) characterized by periodic paralysis, mild QTc 
prolongation, ventricular arrhythmias, and distinctive facial and skel-
etal dysmorphism.32 LQTS occurs in 71% of patients with KCNJ2 
mutations, whereas periodic paralysis is present in 64% and dysmor-
phic features in 78% of probands.32 Cardiac manifestations include 
premature ventricular contractions, nonsustained polymorphic VT, 
bidirectional VT, torsades de pointes, cardiac arrest, and sudden 
death.34 Some patients with KCNJ2 mutations exhibit only arrhyth-
mic phenotype. Nearly 73% of patients with clinical features of ATS 
and KCNJ2 mutations have a prolonged terminal T wave downslope, 
TABLE 1. Updated Diagnostic Criteria for Long QT  
Syndrome Proposed by Schwartz et al9
 Points
Electrocardiographic findings*  
A. QTc† (ms)  
  ≥480 3
  460–479 2
  450–459 (in males) 1
B. QTc† at the fourth minute of recovery from exercise stress 
test ≥480 ms
1
C. Torsade de pointes‡ 2
D. T wave alternans 1
E. Notched T wave in 3 leads 1
F. Low heart rate for age§ 0.5
Clinical history  
A. Syncope‡  
  With stress 2
  Without stress 1
B. Congenital deafness 0.5
Family history  
A. Family members with definite LQTS¶ 1
B. Unexplained sudden cardiac death <30 years of age among 
immediate family members¶
0.5
Score: ≤1 point, low probability of LQTS; 1.5–3 points, intermediate probability of 
LQTS; and ≥3.5 points, high probability.
*In the absence of medications or disorders known to affect these electrocardiographic 
features.
†QTc calculated by Bazett’s formula where QTc QT= / RR .
‡Mutually exclusive.
§Resting heart rate below the second percentile for age.
¶The same family member cannot be counted in A and B.
LQTS indicates long QT syndrome; QTc, QT interval duration in the 12-lead 
electrocardiogram corrected for heart rate.
FIGURE 3. Diagnostic yield of the genetic test in primary 
arrhythmia syndromes. The yield in progressive cardiac con-
duction disease is not well determined and is therefore not 
provided. BrS indicates Brugada syndrome; CPVT, catechol-
aminergic polymorphic ventricular tachycardia; LQTS, long 
QT syndrome; SQTS, short QT syndrome.
TABLE 2. Summary of the Clinical Implications of  Genetic 
Testing in the Management of Patients With Primary 
 Arrhythmia Syndrome and Screening of Their Relatives
 
Diagnostic 
Value
Prognostic 
Value
Therapeutic 
Implications
Family  
Screening
LQTS + + + +
CPVT + + + +
BrS +/– +/– – +
SQTS +/– – – +
PCCD + +/– + +
Detailed information on clinical implications and appropriate references can be 
found in the text.
BrS indicates Brugada syndrome; CPVT, catecholaminergic polymorphic ventricular 
tachycardia; LQTS, long QT syndrome; PCCD, progressive cardiac conductance disease; 
SQTS, short QT syndrome.
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a wide T-U junction, and a biphasic and large U wave, all reflecting 
decreased I
K1
 current.34
LQTS8/Timothy syndrome (CACNA1C) is caused by defective 
L-type calcium channel, Ca
V
1.2, which is responsible for the depo-
larizing calcium current (I
CaL
). Mutations in CACNA1 cause Timothy 
syndrome, a malignant condition characterized by QT prolongation 
(LQTS8, <0.5% of LQTS cases), T wave alternans, lethal arrhyth-
mias, syndactyly, congenital heart disease, immune deficiency, inter-
mittent hypoglycemia, cognitive abnormalities, and autism.35 In a 
study by Splawski et al,35 10 of the 17 affected children (59%) died 
at a mean age of 2.5 years.
LQTS13 (KCNJ5) is caused by a defective muscarinic-gated 
K+ channel (I
KACh
) current. KCNJ5 encodes for the G protein-coupled, 
inwardly rectifying potassium channel subunit Kir3.4.36 Individuals 
harboring mutations in KCNJ5 exhibit only slightly prolonged QTc 
but have a greater T wave morphology combination score based on 
asymmetry, flatness, and notch, and a reduced low-frequency/high-
frequency ratio of heart rate variability as a reflection of cardiac auto-
nomic imbalance.37 Only 25% display a QTc >480 milliseconds.
LQTS14 (CALM1), LQTS15 (CALM2), and LQTS16 
(CALM3) are caused by defective calmodulin, which modifies the 
interactions of calcium signal transduction pathway elements with 
target proteins. In 1 cohort of LQTS patients, calmodulin-related 
functional variants explained 13% of cases.38 Compared with a gen-
eral LQTS cohort, these patients present earlier in life with more 
profound QT prolongation, premature cardiac arrest, or sudden 
death,39,40 and may have overlapping features of LQTS and CPVT.38
Prognostic Value
LQTS1 patients ≤40 years of age have been reported to have 
a higher prevalence of recurrent syncope, aborted cardiac arrest, and 
sudden death than patients with LQTS2 or LQTS3; however, patients 
with LQTS3 have a higher lethality of cardiac events, and the cumu-
lative mortality at 40 years of age is similar (6–8%) among patients 
with LQTS1 through LQTS3 genotypes.41 In the study by Priori 
et al,10 males with either LQTS2 or LQTS3 but not LQTS1 were more 
likely to become symptomatic before 40 years of age. Cardiac arrest 
occurred earlier among males with either LQTS1 or LQTS2, than 
among females. Independent of gender, a QTc ≥500 milliseconds is 
considered the most important predictor of cardiac events in LQTS1, 
LQTS2, or LQTS3.10,42 The risk for cardiac events also varies among 
carriers of different variants within the same affected gene. As such, 
LQTS1 patients with transmembrane mutations exhibited longer QTc 
intervals and had a higher risk of cardiac events than individuals with 
C-terminal mutations.17 Moss et al43 reported that LQTS2 patients 
who carry KCNH2 pore region mutations have a twice higher rate of 
cardiac events than those with mutations in other regions of KCNH2. 
Kapa et al44 showed that nonmissense mutations in KCNQ1, KCNH2, 
and SCN5A have a higher probability to cause LQTS (>99%) regard-
less of location. In contrast, location appears to be critical for patho-
genicity of missense mutations. The corresponding percentage of 
mutations found in definite cases that would cause LQTS was par-
ticularly high, reaching up to 100% in the transmembrane/linker/pore 
regions of KCNH2; the linker, pore, transmembrane, and C-terminus 
of KCNQ1; and the transmembrane/linker of SCN5A. In a topology-
based predictive pathogenicity analysis, Kapplinger et al analyzed 
the rare variants in the C-terminus of Kv7.1 channel (KCNQ1) and 
identified several highly conserved regions (amino acids 349–391, 
509–575, and 585–607) with significantly greater risk.18
Mutations that lead to dominant-negative effect (alteration in 
the gene product so it acts antagonistically and out-competes the wild-
type protein) on I
Ks
 or I
Kr
 lead to a more severe LQTS phenotype, as 
compared to mutations with haploinsufficient behavior.43 Such severe 
phenotype is attributed to the marked alteration of the defective ion 
channel properties, with or without incomplete intracellular process-
ing and defective trafficking of the channel molecule. Rare variants in 
Na
V
1.5 localizing to the Domain III/IV (DIII/DIV) interdomain linker 
have been reported to have a high probability of being pathogenic.45
LQTS patients with multiple mutations have been shown to 
exert more severe phenotype evidenced by longer QTc intervals, 
higher occurrence of cardiac arrhythmias and a nearly 3.5-fold 
higher rate of cardiac arrest, as compared to probands with a single 
or no identified mutation.12
Therapeutic Implications
The 2013 Heart Rhythm Society (HRS), European Heart 
Rhythm Association (EHRA), and Asia Pacific Heart Rhythm Soci-
ety (APHRS) Expert Consensus recommends β-blockers as first-line 
prophylactic treatment for all mutation carriers (class IIa), except 
asymptomatics with a QTc ≤470 milliseconds, in whom decisions 
may be individualized.8 β-Blockers alone can lead to up to a 97% 
reduction in cumulative mortality from LQTS1, and to a lower extent 
from LQTS2.46,47
Lifestyle modifications are an important part of manag-
ing LQTS patients. Genetically positive patients, regardless of the 
phenotype, are advised to avoid QT-prolonging medications (www.
crediblemeds.org). Patients with LQTS1 and LQTS2 are instructed 
to avoid emotional stress and vigorous sports activities, particularly 
swimming for LQTS1, unless an implantable cardioverter defibrilla-
tor (ICD) is implanted, whereas those with LQTS3 do not need exer-
cise restriction. However, patients with LQTS3 should be advised 
to avoid abrupt cessation of rigorous physical exercise, which may 
cause vagal over-activation and predispose to arrhythmias.
Patients with LQTS2 are recommended to avoid arousal 
sources, particularly when resting, such as alarm clocks or loud tele-
phones in the bedroom. Fatality risk, however, remains substantially 
high in patients with Jervell–Lange–Nielsen syndrome, in which 
conventional doses of β-blockers have limited efficacy, and ICD 
therapy is usually indicated.48
For many years, the use of β-blockers in LQTS3 has been 
controversial. Recent studies have shown that β-blocker therapy is 
associated with an 83% reduction of major cardiac events in females, 
but not in males (who had fewer events)42; however, their use requires 
vigilance because slow heart rate may induce rate-dependent ven-
tricular arrhythmias.23 Nadolol (1 mg/kg) seems to be the best treat-
ment option for LQTS patients, but unfortunately, it is not available 
in many countries.
Several sodium channel blockers may be useful in LQTS3. In 
a recent study, mexiletine shortened the QTc interval and caused a 
major reduction of life-threatening arrhythmias in LQT3 patients.49 
However, some mutations have a dual effect on the channel, reduced 
peak current (loss of function), and increased late current (gain of 
function); thus, patients with important loss of function may not be 
candidates to sodium channel blocker therapy. If no functional data 
are available on the specific variant, it is recommended to perform a 
drug challenge test under continuous ECG monitoring before pre-
scription of sodium channel blockers to assess both QTc response 
and the potential proarrhythmic effect or eventual Brugada syndrome 
(BrS)-type ECG pattern.50,51
CATECHOLAMINERGIC POLYMORPHIC 
VENTRICULAR TACHYCARDIA
CPVT is an inherited arrhythmic disorder characterized by 
adrenergically mediated polymorphic or bidirectional VT that may 
degenerate into VF and cause SCD in patients with structurally 
normal hearts (Fig. 2).52 The prevalence of CPVT is roughly esti-
mated to be 1 in 10,000.53 Since the initial description of this severe 
CPVT phenotype, it has become evident that some patients have 
Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
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less aggressive disease and outcome. Nevertheless, when symptoms 
develop early in life, the prognosis is lethal if untreated.
Diagnosis of CPVT
CPVT is diagnosed in the presence of exercise- or emotion-
induced bidirectional VT, characterized by alternating 180°-QRS 
axis on a beat-to-beat basis, or polymorphic VT in patients with 
structurally normal hearts and normal resting ECGs; and/or iden-
tification of a pathogenic mutation in RyR2 or homozygous muta-
tions in CASQ2.1,8 Several cardiovascular conditions may produce 
clinical features resembling CPVT. Patients with LQTS1 experience 
exercise-related arrhythmias or syncope. However, they do not have 
the typical inducible arrhythmias during exercise stress test, as seen 
in CPVT. Bidirectional VT has also been reported in patients with 
ATS54; however, the prolonged QT interval, prominent U waves, lack 
of association of arrhythmias with adrenergic triggers, the presence 
of extracardiac manifestations, and KCNJ2 mutations identified by 
the genetic test allow us to distinguish ATS from CPVT.
Genetic Basis of CPVT and Implications of the 
Genetic Test in CPVT
Known CPVT-associated genes are involved in the calcium 
homeostasis of cardiac cells.55,56 The cardiac ryanodine recep-
tor RyR2 (RyR2) is the principal component of the calcium chan-
nel located on the sarcoplasmic reticulum (SR) of cardiomyocytes 
and functions as the main control for the calcium-induced calcium 
release. Mutations in RyR2 are found in up to 60% of patients with 
strong CPVT phenotype (CPVT1) and autosomal dominant inheri-
tance.57 CASQ2 encodes for cardiac calsequestrin, a luminal calcium-
binding glycoprotein that effectively buffers the SR calcium and 
normally maintains free calcium concentrations below the inhibitory 
level of SR/endoplasmic reticulum Ca2+ ATPase and, thereby pro-
motes calcium reuptake into the SR.58 Compound heterozygous or 
homozygous CASQ2 mutations account for up to 5% of CPVT cases 
(autosomal recessive; CPVT2).1 Autosomal dominant inheritance 
has been reported for CASQ2-CPVT in a single family.59 Mutations 
in RyR2 or CASQ2 cause uncontrolled calcium release from the SR, 
which leads to bidirectional or polymorphic VT mediated by delayed 
after-depolarizations and triggered activity.55
Mutations in TRDN,60 CALM1,61 and CALM3 have been 
detected in individuals with hallmark features of CPVT,62 sometimes 
in association with prolonged QT intervals. Mutated triadin (TRDN) 
renders calsequestrin unable to inhibit the RyR2 activity, allowing 
calcium leaks from the SR and development of clinical features of 
CPVT, with a recessive mode of transmission.60 In 2007, an early-
onset lethal form of CPVT with recessive inheritance in a consan-
guineous Arab family had been linked to a new locus first mapped on 
chromosome 7p14-p22,63 which had been later corrected and mapped 
to the TECLR (4q13 locus).64 Recently, TECRL and CALM2 muta-
tions have been identified in cardiac arrest survivors with clinical 
features of both LQTS and CPVT.64,65
Diagnostic Value
The diagnostic yield of genetic test in CPVT is nearly 60% 
(Fig. 3).1 Testing of at least RyR2 and CASQ2 genes is recommended 
for patients in whom a clinical index of suspicion has been estab-
lished.1 A positive result, besides confirming the diagnosis, is very 
useful to identify other affected family members at risk for SCD 
(Table 2).1,8
Genotype–Phenotype Correlation
Though CPVT typically presents with unremarkable cardiac 
imaging and baseline ECG, several exceptions have been reported. 
RyR2 mutation carriers have lower baseline heart rate, and 19% show 
sinus bradycardia.66 Moreover, a large genomic deletion in exon 3 of 
RyR2 produced an extended clinical profile including sinoatrial node 
and atrioventricular dysfunction, AF, atrial standstill, and dilated car-
diomyopathy, in addition to the classic CPVT phenotype.67 Mutation 
localization has been associated with severity of the phenotype; muta-
tions in the C-terminal channel-forming domain have been associated 
with an increased risk for nonsustained VT, whereas central domain 
mutations have been more frequently associated with supraventricular 
arrhythmias other than sinus bradycardia.66 Studies in CPVT patients 
with and without RyR2 mutations showed that both groups have aver-
age onset of symptoms between 7 and 12 years.52 Clinical features of 
CASQ2- and RyR2-mediated CPVT appear similar; however, because 
CASQ2-related cases are very rare, more reliable data may become 
available with identification of more affected individuals.56
Prognostic Value
When a clear mutation has been identified in RyR2 in an 
asymptomatic person, it has important prognostic value. The pen-
etrance of RyR2-mediated disease is nearly 83%.68 CPVT patients 
generally have a poor prognosis if left untreated, as up to 50% will 
suffer SCD before 20 years of age,69 hence undetected CPVT pres-
ents a frequent cause of unexplained SCD in the young.70 A carrier of 
a heterozygous CASQ2 mutation confers low or no risk of developing 
the disease.
Therapeutic Implications
Family members of CPVT patients, who have a clearly patho-
genic mutation in RyR2 or a homozygous/compound heterozygous 
mutation in CASQ2, have an indication for treatment with β-blockers 
(class IIa).8 The recommended β-blocker is nadolol 1 mg/kg.8 Know-
ing the precise genetic diagnosis allows for the use of certain antiar-
rhythmic drugs or possibly gene therapy in the near future.
The management of CPVT is based on the following strat-
egies: reducing myocardial adrenergic activation with β-blockers; 
preventing spontaneous calcium release from SR and triggered activ-
ity; left cardiac sympathetic denervation; and/or ICD as a back-up 
strategy in high-risk subjects.8 Therapy with flecainide prevents 
ventricular arrhythmias in patients with CPVT not controlled by 
β-blockers.71,72 In a recent randomized clinical trial, therapy with 
flecainide plus a β-blocker significantly reduced ventricular ectopy 
during exercise compared with placebo plus β-blocker or a β-blocker 
alone.73 KCNJ5-mediated CPVT may be more responsive to therapy 
with flecainide or mexiletine rather than β-blockers.74 In contrast, the 
protective effect of left cardiac sympathetic denervation has been 
demonstrated more clearly for patients with RyR2-CPVT than those 
with CASQ2- or KCNJ5-mediated CPVT.75
Gene-specific therapy in animal models of CPVT has been 
performed with optimistic results. Viral gene transfer of wild-type 
CASQ2 into the heart of R33Q mice induced functional long-term 
expression of calsequestrin, and thereby prevented and reverted 
severe manifestations of CPVT.76 Interestingly, allele-specific 
silencing by ribonucleic acid interference prevented life-threaten-
ing arrhythmias in CPVT mice model carriers of the heterozygous 
mutation RyR2-R4496C.77 These promising findings demonstrate 
that gene therapy might be an appealing novel therapeutic option for 
CPVT. Gene therapy is currently being explored at the clinical level.
J WAVE SYNDROMES
J wave syndromes consisting of the BrS and early repolariza-
tion syndrome (ERS) are described by an accentuation of the J wave 
on the ECG and life-threatening ventricular arrhythmias.78 The early 
repolarization pattern on the ECG (distinct J-point elevation, or a 
notch or slur of the terminal part of the QRS with or without an 
ST-segment elevation) is frequently seen in young and apparently 
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healthy individuals, particularly athletes, with a prevalence up to 
40%. In most cases, this is a benign ECG feature,78 but in some 
cases, an association with the development of polymorphic VT and 
VF, both in animals and in humans, has been reported.79,80 These 
findings challenged the benign nature of early repolarization pat-
tern, and it was subsequently referred to as ERS when associated 
with VT/VF in the absence of apparent heart disease.78 BrS and ERS 
share similarities with respect to their clinical manifestations and 
response to pharmacologic therapy, suggesting a similar pathophysi-
ology.78 The 2 clinical entities also share a genetic substrate; so far 
7 culprit genes have been implicated in ERS, all of which, with the 
exception of CACNA2D1, have also been linked to BRS.78 It is pos-
sible that some or all of the knowledge on genetics of BrS can be 
helpful for the diagnosis and management of ERS patients and their 
families. So far, the clinical implications of the genetic test are rela-
tively better established for BrS78; therefore, in this section, we will 
focus on BrS.
Brugada Syndrome
BrS is characterized by a typical ECG pattern of coved-type 
ST-segment elevation with successive negative T wave in the right 
precordial leads (V
1
 to V
3
) with or without cardiac conduction delays 
at different levels, and susceptibility to ventricular tachyarrhythmias 
and SCD (Fig. 2).78 BrS frequently manifests in the 3rd or 4th decade 
of life with ventricular arrhythmias or SCD typically occurring dur-
ing sleep.81 The prevalence of BrS is markedly eightfold higher in 
males, who also have a 3.3-times higher risk for syncope, ICD shock, 
and SCD than females.81 The global prevalence of manifest BrS is 
estimated at 1–5 per 10,000, but the true prevalence might be higher 
due to an often silent course and intermittent ECG pattern.82 The 
manifest form is more prevalent in Asian and Southeast Asian coun-
tries, especially in Japan, Thailand, and the Philippines, where it is 
the major cause of SCD in the young.
Diagnosis of BrS
The diagnosis of BrS is based on its characteristic ECG phe-
notype (resting 12-lead ECG or provocative drug challenge testing), 
clinical, and family history.1
Genetic Basis of BrS and Implications of the Genetic 
Test in BrS
Genetic bases are identified in nearly 30–35% of BrS cases 
(Fig. 3). Mutations in at least 20 genes have been implicated in BrS.83 
The majority of BrS cases are sporadic.84
Loss-of-function mutations in SCN5A account for about 30% 
of BrS cases, and mutations in other genes collectively account for 
an additional 5%.85,86 Mutations in Na
V
1.5 interacting proteins, such 
as its β-subunit gene, have been shown to cause BrS through their 
modifier effect on the Na
V
1.5 (SCN5A) function.87–89 Mutations in 
SCN10A, RANGRF, GPD1L, and SLMAP independently caused BrS 
through reducing the Na
V
1.5 surface membrane expression and the 
I
Na
 current.90–93 Liu et al94 identified TRPM4 mutations in 6% of 248 
BrS patients who tested negative for SCN5A mutations. Additionally, 
Cerrone et al95 found that in some cases, mutations in desmosomal 
plakophilin 2 (PKP2), which are associated with arrhythmogenic 
right ventricular cardiomyopathy (ARVC), can be part of the BrS 
molecular substrate by causing a drastic reduction in I
Na
 specifically 
at the intercalated disc as a result of reduced number of functional 
channels.
Gain-of-function mutations in potassium channel genes KCND3 
(encodes Kv4.3), KCNE5 (X-linked), and KCNE3 (through interacting 
with Kv4.3) independently resulted in an increase of the cardiac tran-
sient outward potassium current (I
to
), and produced BrS phenotype in 
a few cases.96–98 KCNJ8 and ABCC9 encode Kir6.1 and sulfonylurea 
receptor subunit 2A, respectively, which compose the hetero-octameric 
structure of the ATP-sensitive potassium channel (KATP) channel.99 
Gain-of-function mutations in KCNJ8 or ABCC9 have been reported in 
association with severe BrS phenotype.100,101 Among 236 Japanese BrS 
patients, 4 probands, of which 3 exhibited short QT interval, were found 
to have KCNH2 mutations.102
Loss-of-function mutations in calcium channel subunit genes 
CACNA1C, CACNB2b, and CACNA2D1 cause a decrease in the I
CaL
 
current, resulting in a phenotype of BrS combined with short QTc 
interval.103,104
Increasing evidence suggests that except for its SCN5A-
mediated type, BrS is probably an oligogenic disease,105 and clini-
cal studies on large cohorts are required to determine the role of 
the minor genes in the pathogenesis of BrS. It is possible that BrS 
represents the final phenotype of multiple pathophysiologic mech-
anisms sharing the same common pathway. The low penetrance, 
heterogeneous background, and high proportion of genetically 
negative BrS cases favor this hypothesis. Recently, several stud-
ies have reported a clinical and genetic overlap between BrS and 
ARVC as evidenced by ARVC-specific structural and ECG abnor-
malities and identification of PKP2 mutations in BrS patients, and a 
BrS-specific ECG pattern in ARVC patients in response to ajmaline 
challenge test.95,106,107 According to Nademanee et al,108 the under-
lying electrophysiologic mechanism of BrS is delayed depolariza-
tion over the anterior aspect of the right ventricular outflow tract 
epicardium. Catheter ablation over this abnormal area resulted in 
normalization of the BrS-specific ECG pattern and prevented VT/
VF in high-risk BrS patients.108
Diagnostic Value
Comprehensive or SCN5A genetic testing is considered useful 
(class IIa) for any patient with clinical suspicion of BrS. Mutation-
specific genetic testing is recommended for family members after 
identification of a causative mutation in the index patient (class I),1 
and allows for presymptomatic diagnosis in relatives at risk who 
need further clinical follow-up and preventive measures, i.e., antiar-
rhythmic medications, avoiding drugs with sodium channel blocking 
activity, avoiding excessive alcohol intake, prompt treatment of fever 
with antipyretics, etc.
Genotype–Phenotype Correlation
In a study by Smits et al,109 patients with SCN5A-mediated 
BrS had a significantly longer PQ interval and longer His-ventricular 
conduction time (HV) than patients with non-SCN5A BrS. A PQ 
interval of ≥210 milliseconds and HV interval of ≥60 milliseconds 
were predictive for the presence of a SCN5A mutation. This finding 
was validated by a recent study in which BrS patients with SCN5A 
mutations more frequently exhibited conduction abnormalities, than 
those without.110
The exerted ECG pattern can often be a clue for underlying 
genotype in BrS patients. Short QT interval often indicates mutations 
in CACNA1C or CACNB2b, or rarely CACNA2D1.83,104
Prognostic Value
There are limited and conflicting data on the role of genetics 
in BrS prognosis. In the France, Italy, Netherlands, Germany (FIN-
GER) BrS registry, SCN5A mutation status was not an independent 
risk factor for cardiac events (syncope or SCD),111 whereas Nishii et 
al112 and Yamagata et al110 found a significantly higher rate of cardiac 
events and lower shock-free survival rate in SCN5A mutation carri-
ers. In an analysis considering the mutation types, BrS patients with a 
nonsense or frameshift mutation in the SCN5A gene were more likely 
to develop prolonged PR and QRS intervals (increased conduction 
delay at different levels in the heart) and present with syncope, than 
those harboring missense SCN5A mutations.113
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Therapeutic Implications
Currently, genetic test in BrS has no direct therapeutic impli-
cation; however, asymptomatic carriers of clear mutations can be 
subjected to regular control and can advise about potential arrhyth-
mia triggers.
SHORT QT SYNDROME
Short QT syndrome (SQTS) is a very rare and highly lethal 
heritable cardiac channelopathy characterized by brief QT intervals 
on the ECG and high susceptibility to atrial and ventricular arrhyth-
mias and SCD (Fig. 2).114,115 The true incidence is unknown. To date, 
approximately 100 cases of SQTS have been described. In a recent 
study, a QTc ≤330 milliseconds has been observed in 0.05% of the 
population (using Bazett formula for correction), but these individu-
als were asymptomatic and had low-to-intermediate risk of SQTS 
based on clinical and family history.116 This suggests that the preva-
lence of true high-risk SQTS might be even lower. The underlying 
molecular substrates are short atrial and ventricular refractory peri-
ods leading to increased vulnerability to VF.117 Patients can present 
with palpitations or syncope; nevertheless, cardiac arrest at rest can 
be the first manifestation of the disease in up to 40% of cases.113 
Survivors of cardiac arrest have a high recurrence rate of potentially 
fatal arrhythmias. Male and female genders have similar mortality 
and prevalence of the disease.115,118
Patients with SQTS, regardless of the genetic status, and carri-
ers of SQTS-associated mutations, regardless of QTc duration, com-
monly exhibit AF.118 Interestingly, AF has also been noted in children 
and adolescents with SQTS; therefore, SQTS should be considered 
in youngsters with idiopathic (lone) AF.
Diagnosis of SQTS
Gollob et al119 proposed a diagnostic score to assess the likeli-
hood of having SQTS. The HRS/EHRA/APHRS Expert Consensus 
suggested the diagnosis of SQTS in the presence of QTc ≤330 mil-
liseconds.8 SQTS can also be diagnosed in individuals with a QTc 
<360 milliseconds, who have at least one of the following additional 
criteria: a pathogenic mutation in culprit genes, family history of 
SQTS or of SCD by 40 years of age, or survival of a VT/VF episode 
in the absence of other cardiac disease.8 Other ECG characteristics 
include peaked T waves in precordial leads with either short or no 
ST-segment. The QT interval in SQTS is not only too short but also 
fails to adapt to heart rate with reduced or absent shortening during 
exercise.117
Genetic Basis of SQTS and Implications of the 
Genetic Test in SQTS
The first gene described in SQTS was KCNH2 (SQTS1). 
Mutations in KCNH2 dramatically increase I
Kr
 (opposite to the loss-
of-function variant in LQTS2), leading to heterogeneous abbre-
viation of action potential duration and refractoriness, and reduced 
channel affinity to class III antiarrhythmics.120
So far, 5 additional genes have been linked to SQTS.8,121 
The subtypes SQTS1, SQTS2, and SQTS3 are caused by gain-
of-function mutations in potassium channel genes KCNQ1, 
KCNH2, and KCNJ2,120,122,123 which are also linked to LQTS2, 
LQTS1, and LQTS7, respectively, whereas SQTS4, SQTS5, 
and SQTS6 subtypes are caused by loss-of-function muta-
tions in calcium channel genes and can present as either iso-
lated SQTS (CACNA2D1)121 or clinical features of both BrS and 
SQTS (CACNA1C, CACNB2).104 KCNH2 mutations have been 
described in families with paroxysmal AF and SQTS.124 Based 
on the currently available limited data, the penetrance of SQTS 
is estimated to be around 80%.118
Diagnostic Value
The yield of genetic testing has been reported to be nearly 
40% in a combined analysis of all previously reported SQTS cases118 
but has been lower (23–27%) in smaller cohorts (Fig. 3).119,125 Screen-
ing of KCNH2, KCNQ1, and KCNJ2 is recommended as part of the 
diagnostic evaluation in individuals in whom a clinical suspicion for 
SQTS has been established based on clinical and family history, and 
electrocardiographic phenotype.1 Mutation-specific screening is rec-
ommended in family members of patients with a genetically positive 
SQTS (Table 2).
Genotype–Phenotype Correlation
Despite the rarity of SQTS, gene-specific phenotype mark-
ers are beginning to emerge. The T waves tend to be symmetric 
in SQTS1, but asymmetrical with a less steep ascending limb fol-
lowed by a rapid descending limb in SQTS2 to SQTS4 (Fig. 2).126 In 
SQTS2, inverted T waves are commonly seen. In SQTS5, a BrS-type 
ST-elevation in the right precordial leads V
1
 and/or V
2
 may be seen at 
baseline or after administration of sodium channel blockers.126
There is no difference in QT duration between gene-specific 
SQTS groups.118,127 Patients with SQTS1 are typically diagnosed dur-
ing the 4th decade of life, whereas patients with other SQTS genetic 
profiles usually present before 20 years of age.118 SQTS2 patients 
have a strikingly higher prevalence of sick sinus syndrome and bra-
dycardia (SQTS2: 75% vs non-SQTS2: 9%) and AF, compared to 
non-SQT2 patients (SQT2: 63%; non-SQTS2: 21%).118
Prognostic Value
Risk stratification remains the main challenge in SQTS 
patients. The scoring system of Gollob et al119 unfortunately showed 
low sensitivity, predicting low probability of arrhythmic events in 
63% of survivors of cardiac arrest in a study by Mazzanti et al.115 
The uncertainty further increased after 1 study where SQTS patients 
with QTc ≤320 milliseconds neither had a history of syncope nor 
familial event, or experienced any fatal cardiac event during a mean 
follow-up of 5 years.128 Another study reported the QTc value as the 
only risk factor for arrhythmic events in general SQTS population 
(QTc, <360 ms).125 A possible explanation for this discrepancy could 
be the presence of more malignant founder mutations in the cohort 
investigated by Mazzanti et al,115 but it is more likely that, similar to 
other channelopathies, gene–gene interactions and posttranslational 
factors influence the outcome.
Therapeutic Implications
The genetic test in SQTS is useful mainly for family members; 
when positive, cascade screening can be performed to detect relatives 
at risk of SCD.8 But so far, no specific therapy is available for the dif-
ferent genetic forms.
PROGRESSIVE CARDIAC CONDUCTION DISEASE
Progressive cardiac conduction disease (PCCD) is a slow, 
degenerative process that affects the cardiac conduction system with 
or without concomitant structural heart disease.129 The disease is 
caused by a progressive alteration in impulse propagation through 
the His-Purkinje system due to myocardial degeneration, increased 
collagen turnover in the myocardium and fibrosis in the conduction 
system, leading to conduction abnormalities at various levels.
Diagnosis of PCCD
PCCD is diagnosed clinically in the presence of unexplained 
progressive conduction abnormalities in young individuals (<50 
years of age).8 Imaging modalities such as 2D echocardiography or 
cardiac magnetic resonance imaging should be performed to identify 
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potential concomitant heart disease.8 Genetic testing may be consid-
ered (class IIb) in evaluating patients with isolated PCCD or PCCD 
with concomitant structural heart disease (particularly early-onset 
forms), especially in the presence of a positive family history of con-
duction abnormalities, pacemaker implants, or SCD.1,8 Mutation-spe-
cific genetic testing is recommended (class I) for appropriate relatives 
after identification of a PCCD-causative mutation in the proband.1
Genetic Basis of PCCD and Implications of the 
Genetic Test in PCCD
PCCD in structurally normal heart (“isolated PCCD”) is 
caused by mutations in SCN5A, SCN1B, SCN10A, TRPM4, GJA5, and 
KCNK17. There is a consistent overlap between BrS and PCCD, which 
can be explained by the shared pathogenesis as indicated by loss-of-
function SCN5A mutations.130 Mutations in SCN10A (Na
V
1.8) lead to 
atrioventricular (AV) conduction defects and BrS due to its interaction 
with the promoter of SCN5A.131 Additionally, loss-of-function muta-
tions in SCN1B can cause BrS with conduction disease through reduced 
current density and enhanced slow inactivation of the channel.132
Mutations in TRPM4 have been recently implicated in auto-
somal dominant PCCD.133 Makita et al134 demonstrated a causal rela-
tionship between functional alteration in cardiac gap junction protein 
connexin-40 (GJA5) and PCCD with malignant ventricular arrhyth-
mias. In 1 patient with PCCD, a germline mutation in GJA5 led to 
marked reduction of junctional conductance and diffused localiza-
tion of immunoreactive proteins in the vicinity of the plasma mem-
brane without formation of gap junctions.134
PCCD with concomitant structural/congenital heart disease 
has been previously associated with mutations in genes essential for 
cardiac morphogenesis. Alteration in TBX5 and NKX2.5 genes has 
been shown to cause defective expression of connexin-40 and incom-
plete development of the specialized conduction system.135
Diagnostic Value
The diagnostic implication of genetic test in PCCD lies in 
distinguishing genetically mediated disease from acquired forms. 
Genetic testing in PCCD will also help to identify high-risk patients 
with potential overlap syndromes and/or those at risk of other cardiac 
diseases (Table 2).
Genotype–Phenotype Correlation
SCN5A mutations can produce symptoms early in life, and 
additional rhythm disturbances such as AF, atrial flutter, or overlap 
syndrome.136 Mutations in NKX2.5 have been reported in association 
with secundum type atrial septal defect, tetralogy of Fallot, truncus 
arteriosus, L-transposition of great arteries, double-outlet right ven-
tricle, interrupted aortic arch and hypoplastic left heart syndrome, 
with or without conduction defects,137 ventricular noncompaction, and 
sudden death.138 Mutations in TBX5 cause Holt–Oram syndrome, an 
autosomal dominant disorder that affects the bones and the heart.139 
Cardiac manifestations include conduction defects with or without 
concomitant atrial or ventricular septal defects, bradycardia, or AF.
When PCCD is associated with hypertrophic cardiomyopathy 
and Wolff–Parkinson–White syndrome, PRKAG2-mediated disease 
should be suspected.140 Mutations in LMNA have been previously 
associated with PCCD with and without muscular dystrophy and/
or dilated cardiomyopathy. Severe arrhythmias and SCD in these 
patients may precede the development of cardiomyopathy/muscular 
dystrophy phenotype. In LMNA-mediated disease, progressive atrio-
ventricular block is a risk factor for ventricular arrhythmias.141
Prognostic Value
Meregalli et al113 demonstrated a correlation between SCN5A 
mutation type and the clinical and ECG phenotype in BrS or PCCD 
probands. Patients with either a truncation mutation or a severe loss-
of-function missense mutation causing >90% reduction in peak I
Na
 
had a significantly longer PR interval than patients with missense 
mutations causing ≤90% reduction in peak I
Na.
 Truncation mutations 
were associated with a significantly higher rate of syncopal episodes 
compared with missense mutations. It is also known that GJA5-medi-
ated PCCD has early onset and is associated with premature SCD.134 
Patients with LMNA mutations and left ventricular dysfunction also 
have a high risk of SCD. Patients with PRKAG2 mutations may have 
ventricular preexcitation or the Wolff–Parkinson–White syndrome 
caused by nodoventricular/fasciculoventricular accessory pathways; 
therefore, ablation is at high risk for iatrogenic atrioventricular con-
duction blocks.142
Therapeutic Implications
Due to the overlap with BrS and idiopathic VF, patients with 
SCN5A-mediated PCCD should receive active treatment of fever 
to avoid fever-induced ventricular arrhythmias. Targeted genetic 
screening of first-degree relatives of genetically positive index 
patients allows prospective follow-up of asymptomatic mutation 
carriers.
CONCLUSIONS
Genetic testing is currently an essential component in the eval-
uation of patients with suspected inherited arrhythmia syndromes. 
Understanding the molecular substrate of these diseases improves 
the diagnosis, allows tailored therapy and better risk stratification. 
Genetic testing in family members allows the identification of indi-
viduals who need further surveillance to prevent SCD, or even life-
style changes. Ongoing studies are expected to improve the current 
knowledge on genotype–phenotype correlation in these genetically 
heterogeneous cardiac diseases, with a promise of individualized, 
“mutation-specific therapy.” The advancement of in vivo experiments 
will spur the discovery of drugs that target mechanisms underpinning 
these malignant arrhythmias. The promising results of gene therapy 
in animal models will optimistically open doors to the development 
of effective mutation-specific therapies in patients with inherited 
arrhythmia syndromes.
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